About Us

No animal study can predict with certainty how a therapy will perform in human subjects, but with over 600 validated models, we ensure they come as close as possible.

 

Being Correct Is Everything

No animal study can predict with certainty how a therapy will perform in human subjects, yet that is what you need them to do. You need to get as much information from them as possible. Due to study design, the models and technologies available, or lack of proper expertise, most preclinical, in-vivo pharmacological studies are not providing as much information as they could be. These missing insights can derail a pipeline. Missed opportunities are not what you should expect from pharmacology CROs. You should expect more. Now you can. You can expect more from PharmaLegacy because PharmaLegacy has more: more models, more experience, and more focus. We have over 600 validated animal models, including non-human primate models and many humanized rodent models, spanning over 40 different diseases in the fields of cancer, auto-immunity, inflammation and bone. Our staff has an average of 15 – 20 years of pharmacology experience, and most of them have been with PharmaLegacy for more than 5 years. When you search for a pharmacology CRO, set your expectations high. Contact PharmaLegacy and let’s discuss how we can exceed them.

How PharmaLegacy is Different

PharmaLegacy is equipped to obtain higher-quality pharmacological data across a greater number of diseases than any other CRO.

We have the greatest collection of extensively validated pre-clinical models. We have over 600 validated animal models of disease spanning over 40 different diseases in the fields of cancer, bone, auto-immunity and inflammation.

We have the most highly experienced and specialized staff in in vivo pharmacology. Our scientific staff have an average of over 15 years of pharmacology experience. We pride ourselves on employee retention, which means you’ll have stable scientific teams who are experienced working with each other and our advanced models.

We utilize non-human primate animal models and many humanized rodent models, which provide more clinically relevant data than other types of in vivo models.

We have a number of proprietary platforms which supplement our capabilities in preclinical pharmacology.

We have helped hundreds of clients with IND filings to both FDA and CFDA (China) for their therapeutic biologics candidates in a variety of immune disease and oncology. Our animal vivarium is fully accredited by AAALAC and houses species ranging from rodents, rabbits and other small animals to NHP. We also conduct adjacency studies in PK/PD, molecular pharmacology and preliminary toxicology. Overall, we provide complete preclinical pharmacology services for early proof-of-concept of therapeutics and fulfillment of regulatory requirements.

Delivering the most accurate and confident scientific answers and securing the greatest IP protection for our clients are the lifeblood of our services. Operations based on international GLP and QA best practices.

Research data is electronically managed by BioBook (IDBS, UK).

FDA Part 11 compliant

Maximum protection of client’s work and intellectual property

Expedited professional reports writing for regulatory filings

150,000 ft2 facility with 43,000 ft2 of SPF and conventional vivarium to house 20,000 rodents and large animals.

On-site capacity for up to 350 non-human primates.

Partnerships with three premium non-human primate centers having capacity for 30,000 monkeys (Cynomolgus and Rhesus)Capacity to run 200 animal studies concurrently while strictly following AAALAC and ILAC guidelines.

Web-based live video streaming allows remote monitoring of operations from any location worldwide.

24/7 access to PharmaLegacy representatives.

 

Aspiring to accelerate our clients’ missions to develop new therapies, PharmaLegacy provides quality preclinical pharmacology services with faster turnaround to support IND/IDE for pharmaceutical, biotech, and orthopaedic device companies around the world.

There’s a lot on the line.

LET PHARMALEGACY GET THE CORRECT ANSWERS.